Echelon Wealth Partners analyst Stefan Quenneville reiterated a Buy rating on Valeo Pharma (VPHIF – Research Report) today and set a price target of C$1.00. The company’s shares closed last Tuesday at $0.26.
According to TipRanks, Quenneville is an analyst with an average return of -11.5% and a 30.53% success rate. Quenneville covers the Healthcare sector, focusing on stocks such as Valeo Pharma, Cognetivity Neurosciences, and Nanalysis Scientific.
Currently, the analyst consensus on Valeo Pharma is a Moderate Buy with an average price target of $0.73.
See today’s best-performing stocks on TipRanks >>
VPHIF market cap is currently $25.7M and has a P/E ratio of -1.37.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Valeo Pharma Inc a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing or similar arrangements. Its current markets its product Synacthen Depot which is a synthetic ACTH product that is used in conditions where the production of natural cortisol and other hormones is desired.
